[{"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-001", "question": "A 48-year-old woman with a history of systemic lupus erythematosus (SLE) on hydroxychloroquine and low-dose prednisone presents with 3 weeks of progressive dyspnea on exertion and dry cough. High-resolution CT shows diffuse ground-glass opacities with superimposed fine reticulation and subpleural sparing. Bronchoalveolar lavage reveals lymphocytic predominance (65%) with CD4:CD8 ratio of 0.8. Pulmonary function tests show a restrictive pattern with severely reduced DLCO (38% predicted). Which of the following is the most appropriate next step in management?", "options": ["Initiate high-dose intravenous methylprednisolone followed by oral prednisone 1 mg/kg/day", "Add mycophenolate mofetil to current immunosuppression", "Discontinue hydroxychloroquine and observe for 4 weeks", "Perform surgical lung biopsy to confirm usual interstitial pneumonia pattern", "Start rituximab therapy without additional testing"], "answer": "B", "answer_index": 1, "explanation": "The presentation is classic for lymphocytic interstitial pneumonia (LIP) associated with SLE, characterized by ground-glass opacities with reticulation, lymphocytic BAL, and low CD4:CD8 ratio. LIP in connective tissue disease typically requires more aggressive immunosuppression beyond steroids alone. Mycophenolate mofetil is the preferred steroid-sparing agent for SLE-associated interstitial lung disease with this pattern. High-dose steroids alone (A) are insufficient for progressive LIP. Hydroxychloroquine cessation (C) is unlikely to reverse established ILD. Surgical biopsy (D) is unnecessary with characteristic HRCT and BAL findings. Rituximab (E) is reserved for refractory cases after conventional immunosuppression fails.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient's clinical presentation and test results are consistent with Systemic Lupus Erythematosus (SLE)-associated Interstitial Lung Disease (ILD), specifically exhibiting a Nonspecific Interstitial Pneumonia (NSIP) pattern.\n\n1.  Diagnosis:\n    *   Presentation: 3 weeks of progressive symptoms suggests a subacute process.\n    *   HRCT: Diffuse ground-glass opacities (GGO) with subpleural sparing is the hallmark radiographic pattern of cellular NSIP. The presence of GGO suggests active inflammation (alveolitis) that is potentially reversible.\n    *   BAL: Lymphocytic predominance supports an inflammatory/cellular interstitial process (like cellular NSIP) rather than a fibrotic one (like UIP, which often has neutrophils) or infection (which would show neutrophils or organisms, though PCP is a differential, usually PCP presents with fever and profound hypoxia; in the context of SLE questions, this constellation points to SLE-ILD).\n    *   Physiology: Restrictive pattern with severely reduced DLCO indicates significant disease severity.\n\n2.  Management:\n    *   Corticosteroids (Option A): For symptomatic, progressive, or severe SLE-ILD (especially cellular NSIP or acute lupus pneumonitis), the first-line treatment is moderate-to-high-dose systemic corticosteroids to suppress inflammation and prevent fibrosis. Pulse-dose IV methylprednisolone followed by high-dose oral prednisone is appropriate given the severity (DLCO 38%) and rapid progression.\n    *   Mycophenolate Mofetil (Option B): MMF is a preferred long-term maintenance/steroid-sparing agent for SLE-ILD. However, adding it to the current *low-dose* prednisone without first initiating high-dose corticosteroid induction would likely be insufficient to arrest the acute progression of the disease. It is often initiated *alongside* high-dose steroids, but the steroid pulse is the critical immediate intervention.\n    *   Discontinue Hydroxychloroquine (Option C): Hydroxychloroquine is not a common cause of ILD (unlike methotrexate), and discontinuing it would risk an SLE flare. Observation is inappropriate for a patient with severe and progressive respiratory compromise.\n    *   Surgical Lung Biopsy (Option D): A biopsy is not indicated when the clinical and radiographic data are compelling for a CTD-associated ILD, particularly the NSIP pattern in SLE. The risks of biopsy in a patient with a DLCO of 38% outweigh the benefits.\n    *   Rituximab (Option E): This is typically reserved for refractory cases and is not first-line therapy.\n\nTherefore, the most appropriate next step is aggressive anti-inflammatory therapy with corticosteroids.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-002", "question": "A 62-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab presents with acute-onset diplopia, ptosis, and dysphagia 6 weeks after initiation. Neurological exam reveals bilateral asymmetric ophthalmoparesis, fatigable ptosis, proximal muscle weakness, and normal pupillary responses. Repetitive nerve stimulation shows 25% decrement at 3Hz. Which of the following is the most specific diagnostic test to confirm the underlying pathophysiology?", "options": ["Anti-acetylcholine receptor antibody titer", "Anti-MuSK antibody testing", "Anti-LRP4 antibody assay", "CT chest with contrast for thymoma", "Serum anti-striational muscle antibody testing"], "answer": "E", "answer_index": 4, "explanation": "This presentation represents immune checkpoint inhibitor-induced myasthenia gravis, which is strongly associated with anti-striational muscle antibodies (particularly anti-titin) in paraneoplastic contexts. While anti-AChR antibodies (A) are positive in most generalized MG, anti-striational antibodies have higher specificity for thymoma-associated and paraneoplastic MG in cancer patients on immunotherapy. Anti-MuSK (B) and anti-LRP4 (C) antibodies are associated with different MG subtypes but not specifically with paraneoplastic forms. CT for thymoma (D) is indicated but not the most specific test for pathophysiology. The combination of immune checkpoint therapy with these neurological findings makes anti-striational antibodies the key diagnostic marker.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with clinical features characteristic of Myasthenia Gravis (MG), including asymmetric ophthalmoparesis, fatigable ptosis, bulbar symptoms (dysphagia), and proximal muscle weakness. The temporal association with the initiation of immune checkpoint inhibitors (nivolumab and ipilimumab) suggests an immune-related adverse event (irAE), specifically ICI-associated myasthenia gravis.\n\nThe Repetitive Nerve Stimulation (RNS) finding of a 25% decrement at 3Hz confirms a postsynaptic neuromuscular junction transmission defect, which is the hallmark electrophysiological finding in MG. To confirm the specific underlying pathophysiology (an autoimmune attack on the postsynaptic membrane), the identification of the pathogenic autoantibody is the most specific test.\n\n1.  Anti-acetylcholine receptor (AChR) antibody titer (Option A): Anti-AChR antibodies are the most common pathogenic antibodies in MG, found in approximately 85% of generalized idiopathic MG cases and about 60-70% of ICI-associated MG cases. These antibodies directly cause the pathophysiology by blocking, cross-linking, and accelerating the degradation of acetylcholine receptors. Their presence typically confirms the diagnosis with high specificity.\n2.  Anti-MuSK antibody (Option B) and Anti-LRP4 antibody (Option C): These are found in subsets of seronegative MG patients but are rare in the context of ICI-associated MG.\n3.  CT chest (Option D): While thymomas are associated with MG, imaging identifies anatomical associations rather than the physiological mechanism of the neuromuscular blockade. Additionally, this patient has a known malignancy causing the immune dysregulation via therapy.\n4.  Anti-striational muscle antibody (Option E): These antibodies are often found in patients with thymoma-associated MG and are frequently positive in ICI-associated MG (often correlating with concurrent myositis). However, they are less specific for the neuromuscular junction defect itself compared to anti-AChR antibodies, as they target intracellular muscle proteins (like titin) rather than the surface receptors responsible for neuromuscular transmission.\n\nTherefore, the anti-AChR antibody titer is the best test to confirm the antibody-mediated pathophysiology of the neuromuscular junction defect observed.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-003", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe headache, photophobia, and confusion. BP is 150/95 mmHg. MRI brain shows bilateral cortical and subcortical edema predominantly in posterior parietal and occipital lobes, with patchy cortical diffusion restriction. MR venography is normal. She has no proteinuria. Which of the following is the most likely underlying vascular pathophysiology?", "options": ["Cerebral venous sinus thrombosis", "Posterior reversible encephalopathy syndrome", "Reversible cerebral vasoconstriction syndrome", "Eclampsia without hypertension", "Posterior circulation ischemic stroke"], "answer": "C", "answer_index": 2, "explanation": "This represents reversible cerebral vasoconstriction syndrome (RCVS) in pregnancy, characterized by thunderclap headache, normal venography, and posterior-predominant edema with diffusion restriction. The key distinction from PRES (B) is the presence of cortical diffusion restriction and more severe headache. RCVS involves segmental cerebral arterial vasoconstriction rather than hypertensive breakthrough autoregulation. Cerebral venous thrombosis (A) would show venous occlusion. Eclampsia (D) typically requires significant hypertension and proteinuria. Posterior circulation stroke (E) would show more defined arterial territory infarction rather than patchy cortical involvement.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical presentation of a pregnant woman with acute headache, confusion, visual disturbances (photophobia), and hypertension (150/95 mmHg defines hypertension in pregnancy), combined with the classic MRI findings, points to a specific diagnosis.\n\n1.  MRI Findings: The presence of \"bilateral cortical and subcortical edema predominantly in posterior parietal and occipital lobes\" is the hallmark radiological description of Posterior Reversible Encephalopathy Syndrome (PRES). While vasogenic edema is the main finding, patchy cortical diffusion restriction can occur in PRES (representing areas of cytotoxic edema or ischemia) and does not exclude the diagnosis.\n2.  Clinical Context: Pregnancy and hypertension (even moderate) are major risk factors for PRES. The pathophysiology involves the failure of cerebral autoregulation and/or endothelial dysfunction leading to blood-brain barrier breakdown and vasogenic edema.\n3.  Ruling out other options:\n    *   A. Cerebral venous sinus thrombosis: Ruled out by the normal MR venography.\n    *   C. Reversible cerebral vasoconstriction syndrome (RCVS): While this condition shares features with PRES and can coexist, the primary MRI finding of extensive posterior edema is the definition of PRES. RCVS is characterized primarily by multifocal arterial constriction on angiography and thunderclap headache.\n    *   D. Eclampsia without hypertension: First, the patient *is* hypertensive (BP 150/95 mmHg). Second, eclampsia is defined by the occurrence of seizures, which are not mentioned.\n    *   E. Posterior circulation ischemic stroke: While ischemia can cause diffusion restriction, the bilateral, symmetric distribution of edema involving the parietal and occipital white matter is distinct for PRES. Ischemic strokes usually follow specific vascular territories and present primarily with frank diffusion restriction rather than extensive vasogenic edema.\n\nTherefore, the clinical and radiological picture represents PRES.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-004", "question": "A 57-year-old man with alcoholic cirrhosis (Child-Pugh B) presents with fever, abdominal pain, and altered mental status. Paracentesis reveals ascitic fluid with 450 neutrophils/mm³. Blood and ascitic fluid cultures grow extended-spectrum beta-lactamase (ESBL) producing Escherichia coli. He receives meropenem for 72 hours but remains febrile with worsening encephalopathy. Repeat paracentesis shows 520 neutrophils/mm³ with negative cultures. Which of the following is the most appropriate next step?", "options": ["Add intravenous vancomycin for possible MRSA coverage", "Switch to piperacillin-tazobactam given ESBL resistance patterns", "Perform urgent transjugular intrahepatic portosystemic shunt placement", "Administer intravenous albumin 1.5 g/kg on day 1 and 1.0 g/kg on day 3", "Add intravenous metronidazole for anaerobic coverage"], "answer": "C", "answer_index": 2, "explanation": "This scenario describes recurrent or persistent spontaneous bacterial peritonitis (SBP) with treatment failure, which in the context of cirrhosis carries high mortality. TIPS placement reduces portal pressure and may improve outcomes in refractory SBP by decreasing bacterial translocation. Albumin (D) is indicated for SBP but already should have been given initially. Antibiotic changes (A, B, E) are inappropriate with negative repeat cultures and clinical deterioration despite appropriate initial therapy. In refractory SBP with ongoing inflammation despite adequate antibiotics, TIPS can be life-saving by addressing the underlying pathophysiology of portal hypertension.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with alcoholic cirrhosis and Spontaneous Bacterial Peritonitis (SBP). The initial diagnosis was confirmed with an ascitic fluid neutrophil count of 450/mm³ and cultures growing ESBL-producing *E. coli*. The patient was treated with meropenem, which is the appropriate carbapenem therapy for ESBL organisms.\n\nAfter 72 hours, the patient has clinical signs of treatment failure (persistent fever, worsening encephalopathy) and laboratory evidence of failure (ascitic fluid neutrophils increased to 520/mm³). According to AASLD guidelines, a lack of decrease in PMN count by at least 25% after 48 hours indicates treatment failure.\n\nThe steps for managing SBP treatment failure are:\n1.  Evaluate for Secondary Bacterial Peritonitis: Features include very high protein, low glucose, high LDH, or polymicrobial growth. While we cannot perform a CT scan within the options, this must be considered. However, the initial culture was monomicrobial, and repeat culture is negative.\n2.  Modify Antibiotic Therapy: If secondary peritonitis is excluded or while awaiting evaluation, antibiotics should be broadened to cover resistant organisms that are not covered by the current regimen. Since the patient is already on meropenem (which covers ESBL GNRs, Pseudomonas, and Anaerobes), the gap in coverage typically involves resistant Gram-positive organisms (such as MRSA, *Enterococcus faecium*, or resistant *Enterococcus faecalis*) or fungi.\n\nLet's evaluate the options:\n*   A. Add intravenous vancomycin for possible MRSA coverage: This is the most appropriate step to broaden coverage for resistant Gram-positive organisms (MRSA, Enterococci) which can cause superinfection or be the primary pathogen in non-responding cases (especially if the initial *E. coli* was a coinfection or successfully treated but a resistant bug persists).\n*   B. Switch to piperacillin-tazobactam: This is inappropriate. Piperacillin-tazobactam is generally considered inferior to carbapenems for severe ESBL infections and would be a \"step down\" or lateral move, not addressing potential resistance.\n*   C. Perform urgent TIPS: TIPS is contraindicated in the setting of active infection (sepsis) and severe hepatic encephalopathy.\n*   D. Administer intravenous albumin: Albumin is standard adjunctive therapy for SBP (1.5 g/kg on day 1 and 1.0 g/kg on day 3) to prevent hepatorenal syndrome. While the patient likely needs this (or should have received it), the *immediate* \"next step\" to address the *worsening infection* (rising PMNs) and treatment failure is modifying the antimicrobial regimen. Albumin does not treat the infection.\n*   E. Add intravenous metronidazole: Meropenem has excellent anaerobic coverage (`Bacteroides`, `Clostridium`, etc.). Adding metronidazole adds no significant benefit and is redundant.\n\nTherefore, broadening antibiotic coverage to include resistant Gram-positives with Vancomycin is the correct management for SBP treatment failure on a carbapenem.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-005", "question": "A 41-year-old woman with antiphospholipid syndrome (triple positive) on warfarin (INR 2.8) presents with acute right hemiparesis and aphasia. CT angiogram shows complete occlusion of the left middle cerebral artery M1 segment. She is 4 hours from symptom onset. Which of the following is the most appropriate acute intervention?", "options": ["Administer intravenous tissue plasminogen activator", "Proceed with mechanical thrombectomy without thrombolysis", "Give intravenous heparin bolus followed by infusion", "Administer intra-arterial thrombolysis via catheter", "Continue warfarin and add aspirin 325 mg"], "answer": "B", "answer_index": 1, "explanation": "In antiphospholipid syndrome with acute large vessel occlusion, mechanical thrombectomy is indicated regardless of anticoagulation status. tPA (A) is contraindicated with therapeutic INR >1.7. Heparin (C) adds bleeding risk without proven benefit in acute stroke with therapeutic anticoagulation. Intra-arterial thrombolysis (D) carries similar bleeding risks as IV tPA. Continuing warfarin with aspirin (E) does not address acute occlusion. Mechanical thrombectomy has shown benefit up to 24 hours in selected patients and is not contraindicated by therapeutic anticoagulation if the procedure can be performed safely.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Here is the step-by-step reasoning for the chosen answer:\n\n1.  Assess Eligibility for IV Thrombolysis (tPA): The patient presents within the typical time window for intravenous thrombolysis (4 hours is < 4.5 hours). However, she is on warfarin and has an International Normalized Ratio (INR) of 2.8. According to the American Heart Association/American Stroke Association (AHA/ASA) guidelines, IV alteplase is contraindicated in patients taking vitamin K antagonists (like warfarin) if the INR is greater than 1.7. Therefore, Option A is incorrect due to the high risk of intracranial hemorrhage.\n\n2.  Assess Indication for Mechanical Thrombectomy: The patient has a Large Vessel Occlusion (LVO) involving the M1 segment of the middle cerebral artery and presents within the standard 6-hour window for endovascular therapy. Mechanical thrombectomy is the standard of care for acute ischemic stroke caused by LVO in the anterior circulation.\n\n3.  Determine the Best Course of Action: Since the patient is eligible for mechanical thrombectomy based on the occlusion site and timing but is ineligible for IV tPA due to her therapeutic anticoagulation (INR 2.8), the most appropriate intervention is to proceed directly to mechanical thrombectomy. Guidelines explicitly state that patients eligible for mechanical thrombectomy who have a contraindication to IV alteplase should be treated with mechanical thrombectomy.\n\n4.  Evaluate Other Options:\n    *   Option C (Heparin) is generally not recommended for the treatment of acute ischemic stroke due to the risk of hemorrhagic transformation, especially in the setting of a large infarction, and standard practice prioritizes revascularization first.\n    *   Option D (Intra-arterial thrombolysis) is less effective and has a higher safety risk profile compared to modern mechanical thrombectomy devices (stent rerievers/aspiration).\n    *   Option E (Aspirin) fails to address the active occlusion causing the stroke and does not provide revascularization.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-006", "question": "A 29-year-old woman presents with 6 months of progressive dyspnea and palpitations. Echocardiogram shows severe pulmonary hypertension (RVSP 85 mmHg) with right ventricular dilation but normal left heart function. Right heart catheterization confirms pre-capillary pulmonary hypertension (mPAP 48 mmHg, PAWP 10 mmHg). High-resolution CT shows mosaic attenuation and enlarged central pulmonary arteries. Ventilation-perfusion scan reveals multiple segmental perfusion defects. Which of the following is the definitive diagnostic test?", "options": ["Pulmonary angiogram", "CT pulmonary angiogram", "Genetic testing for BMPR2 mutation", "Lung biopsy", "Exercise right heart catheterization"], "answer": "A", "answer_index": 0, "explanation": "This presentation is classic for chronic thromboembolic pulmonary hypertension (CTEPH). While V/Q scan is the screening test, pulmonary angiography remains the gold standard for defining surgical accessibility and planning pulmonary endarterectomy. CT pulmonary angiography (B) provides anatomical detail but has lower sensitivity for chronic thromboembolic material. Genetic testing (C) is for heritable pulmonary arterial hypertension, not CTEPH. Lung biopsy (D) is contraindicated in severe pulmonary hypertension. Exercise catheterization (E) may confirm exercise-induced PH but doesn't diagnose CTEPH. Pulmonary angiography is essential for determining operability in CTEPH.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "In this clinical scenario, the patient has severe pre-capillary pulmonary hypertension. The key finding is the ventilation-perfusion (V/Q) scan showing multiple segmental perfusion defects. In the context of pulmonary hypertension, this finding is highly specific for Chronic Thromboembolic Pulmonary Hypertension (CTEPH, WHO Group 4). Pulmonary Arterial Hypertension (PAH) would typically show a normal V/Q scan or mottled subsegmental defects.\n\nThe question asks for the *definitive diagnostic test*.\n1.  Pulmonary angiogram (Digital Subtraction Angiography - DSA): This is considered the gold standard for confirming the diagnosis of CTEPH and, more importantly, for assessing the specific vascular anatomy to determine eligibility for pulmonary endarterectomy (PEA). It can visualize rings, webs, and organized thrombi even in distal vessels that might be missed by CTPA.\n2.  CT pulmonary angiogram (CTPA): While commonly used and highly effective, it is often considered the first-line anatomical confirmatory test, but conventional pulmonary angiography remains the definitive reference standard, especially for surgical planning.\n3.  Genetic testing for BMPR2: This is used for Heritable PAH. The V/Q scan findings make PAH unlikely compared to CTEPH.\n4.  Lung biopsy: This is generally contraindicated in patients with severe pulmonary hypertension due to the high risk of bleeding and hemodynamic collapse. It is not part of the standard workup for CTEPH.\n5.  Exercise RHC: This is used to diagnose early or exercise-induced PH or HFpEF, but the patient already has severe resting PH.\n\nGiven the V/Q findings, the condition is CTEPH, and the definitive test to confirm and plan treatment is the pulmonary angiogram.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-007", "question": "A 63-year-old man with diabetes and peripheral arterial disease presents with 2 hours of acute, painless monocular vision loss in the right eye. Visual acuity is hand motion only. Funduscopy reveals a pale retina with cherry-red spot and boxcarring of retinal vessels. Carotid duplex shows 90% stenosis of the right internal carotid artery. Which of the following is the most urgent intervention?", "options": ["Intravenous tissue plasminogen activator", "Anterior chamber paracentesis", "Immediate carotid endarterectomy", "Hyperbaric oxygen therapy", "Intra-arterial thrombolysis via ophthalmic artery catheterization"], "answer": "E", "answer_index": 4, "explanation": "This describes central retinal artery occlusion (CRAO) with cherry-red spot and boxcarring, indicating acute ischemia. Intra-arterial thrombolysis via selective ophthalmic artery catheterization within 6-12 hours may restore vision in CRAO, though evidence is limited. IV tPA (A) is not standard for CRAO. Anterior chamber paracentesis (B) is historical but ineffective. Carotid endarterectomy (C) addresses the source but not the acute occlusion. Hyperbaric oxygen (D) has limited evidence. Given the time window and severity, selective intra-arterial thrombolysis offers the best chance for visual recovery in this acute setting.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with Central Retinal Artery Occlusion (CRAO), evidenced by acute painless monocular vision loss, a cherry-red spot on the macula, and boxcarring of retinal vessels. CRAO is an ophthalmologic emergency where retinal infarction occurs rapidly (within 90–100 minutes to a few hours). The goal of immediate therapy is to restore retinal blood flow.\n\nThe most urgent interventions generally act to lower intraocular pressure (IOP) to increase the perfusion pressure gradient across the central retinal artery, potentially dislodging the embolus into a more peripheral branch where it causes less visual field loss.\n\n1.  Anterior chamber paracentesis (Option B): This is an immediate, bedside procedure involving the removal of aqueous humor to rapidly lower IOP. Alongside ocular massage and IOP-lowering medications (like acetazolamide), this is considered the standard initial therapeutic maneuver for acute CRAO in many guidelines and exam contexts because it can be performed instantly to attempt vision salvage.\n2.  Intravenous tissue plasminogen activator (Option A): While recent guidelines indicate IV tPA may be effective if administered early (within 4.5 hours), it is not the universally accepted first-line standard of care in all settings due to bleeding risks and inconsistent evidence of benefit compared to conservative therapy. Furthermore, tPA administration requires neuroimaging (CT/MRI) first to rule out hemorrhage, which causes a delay compared to immediate bedside maneuvers.\n3.  Immediate carotid endarterectomy (Option C): This is indicated for the secondary prevention of future ischemic events (strokes) in patients with symptomatic carotid stenosis. It is not the management for the acute occlusion of the retinal artery itself, and the surgery takes time to organize, by which point the retina would be permanently infarcted.\n4.  Hyperbaric oxygen therapy (Option D): This acts to increase oxygen delivery to the retina from the choroidal circulation. While beneficial, it is often considered adjunctive, and access is frequently limited, making it less \"urgent\" or universally applicable than immediate IOP reduction.\n5.  Intra-arterial thrombolysis (Option E): This requires significant mobilization of resources (interventional radiology) and time. The EAGle trial (2010) failed to show a clear benefit over conservative treatment and highlighted safety concerns.\n\nGiven the options and the need for immediate action to save the eye in a standard exam context, anterior chamber paracentesis is the most appropriate urgent intervention listed.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-008", "question": "A 38-year-old woman with history of mitral valve prolapse presents with 3 weeks of daily fevers, night sweats, and new-onset diastolic murmur. Blood cultures are negative after 72 hours. Transthoracic echocardiogram shows a 12mm mobile vegetation on the anterior mitral leaflet with severe mitral regurgitation. Which of the following organisms is most likely responsible?", "options": ["Streptococcus gallolyticus", "Coxiella burnetii", "Bartonella henselae", "Tropheryma whipplei", "Abiotrophia defectiva"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests culture-negative endocarditis in a patient with pre-existing mitral valve disease. Bartonella henselae is the most common cause of culture-negative endocarditis in patients with valve abnormalities, particularly associated with negative blood cultures, subacute presentation, and large vegetations. Coxiella burnetii (B) typically causes Q fever endocarditis with exposure history. Streptococcus gallolyticus (A) is culture-positive and associated with colorectal pathology. Tropheryma whipplei (D) causes Whipple's disease with systemic symptoms. Abiotrophia (E) is nutritionally variant but usually culture-positive. Bartonella requires serology or PCR for diagnosis and responds to specific antibiotic regimens.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This question describes a case of culture-negative endocarditis. The patient has clinical signs of infective endocarditis (fevers, night sweats, new murmur) and echocardiographic evidence of a large vegetation (12 mm) and severe valvular regurgitation, yet standard blood cultures are negative.\n\nHere is a breakdown of the options:\n\n*   A. *Streptococcus gallolyticus*: This organism (formerly *S. bovis*) grows readily in standard blood cultures. Cases are strongly associated with colorectal cancer. It would not typically present as culture-negative endocarditis.\n*   B. *Coxiella burnetii*: This is the causative agent of Q fever and is a major cause of culture-negative endocarditis. However, the echocardiographic appearance of *Coxiella* endocarditis is distinct. It typically causes valvular fibrosis and thickening; vegetations are usually absent or very small and nodular. Assessing a patient with a large (12 mm), mobile vegetation makes *Coxiella* unlikely.\n*   C. *Bartonella henselae*: *Bartonella* species (including *B. henselae* and *B. quintana*) are leading causes of culture-negative endocarditis (often transmitted by cat scratches or lice, respectively). Unlike *Coxiella*, _Bartonella_ endocarditis frequently presents with large, potentially destructive vegetations on the valve, similar to those seen in standard bacterial endocarditis. The combination of negative cultures and a large vegetation on echocardiography strongly points to *Bartonella*.\n*   D. *Tropheryma whipplei*: This causes Whipple's disease. While it can cause culture-negative endocarditis (often without the classic gastrointestinal malabsorption signs), it is a very rare cause distinct from the more common *Bartonella* and *Coxiella*.\n*   E. *Abiotrophia defectiva*: This is a nutritionally variant streptococcus (NVS). While historically difficult to grow (requiring pyridoxal or cysteine), modern automated blood culture systems usually flag positive for these organisms, though subculturing them remains difficult. True culture-negativity at 72 hours is more characteristic of intracellular pathogens like *Bartonella* or *Coxiella*.\n\nTherefore, based on the presence of a large vegetation in a culture-negative setting, *Bartonella henselae* is the most likely etiology among the choices.\n\nThe answer is (C)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-009", "question": "A 52-year-old woman with rheumatoid arthritis on methotrexate presents with progressive dyspnea and dry cough. High-resolution CT shows extensive ground-glass opacities with centrilobular nodules and tree-in-bud pattern predominantly in upper lobes. Bronchoscopy with transbronchial biopsy reveals non-necrotizing granulomas with multinucleated giant cells. Which of the following is the most likely diagnosis?", "options": ["Methotrexate pneumonitis", "Rheumatoid arthritis-associated interstitial lung disease", "Mycobacterium avium complex infection", "Sarcoidosis", "Hypersensitivity pneumonitis"], "answer": "C", "answer_index": 2, "explanation": "The combination of upper lobe predominance, tree-in-bud pattern, and non-necrotizing granulomas in an immunocompromised patient on methotrexate is classic for nontuberculous mycobacterial infection, particularly MAC. Methotrexate pneumonitis (A) typically shows diffuse alveolar damage pattern. RA-ILD (B) usually shows UIP or NSIP patterns. Sarcoidosis (D) shows perilymphatic nodules and hilar adenopathy. Hypersensitivity pneumonitis (E) shows centrilobular nodules but usually without tree-in-bud or upper lobe predominance. Immunosuppressed patients on methotrexate are at increased risk for NTM infections, which can mimic granulomatous diseases.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This question describes a patient with rheumatoid arthritis (RA) treated with methotrexate (MTX) who presents with respiratory symptoms. The key to answering this question lies in integrating the radiologic and pathologic findings with the clinical context.\n\n1.  Imaging (HRCT): The presence of \"tree-in-bud\" opacities is the most discriminating feature. This pattern represents impaction of bronchioles with mucus, pus, or fluid and is highly characteristic of cellular bronchiolitis. The differential diagnosis for tree-in-bud is primarily infection (bacterial, viral, but classically mycobacterial such as TB or NTM like MAC) or aspiration. It is *not* a typical feature of drug-induced pneumonitis (which usually shows diffuse GGO or consolidation), Sarcoidosis (which shows perilymphatic nodules), or classic RA-ILD (which shows UIP or NSIP patterns).\n\n2.  Pathology: The biopsy reveals non-necrotizing granulomas. While non-necrotizing granulomas are the hallmark of Sarcoidosis and can be seen in Methotrexate pneumonitis and Hypersensitivity Pneumonitis, they are also frequently seen in Mycobacterium avium complex (MAC) infections (unlike TB, which is classically necrotizing/caseating). The \"Hard\" tubercles of Sarcoidosis are distinct, but NTM granulomas can mimic them.\n\n3.  Synthesis:\n    *   Sarcoidosis (D): ruled out by the \"tree-in-bud\" pattern (Sarcoidosis is perilymphatic and lymphatic-distribution).\n    *   Methotrexate pneumonitis (A): Can show non-necrotizing granulomas, but the \"tree-in-bud\" pattern is inconsistent with drug toxicity; it suggests an infectious etiology.\n    *   RA-ILD (B): typically presents as fibrosis (UIP) or inflammation (NSIP), not granulomatous bronchiolitis with tree-in-bud.\n    *   Hypersensitivity Pneumonitis (E): Presents with centrilobular nodules and non-necrotizing granulomas. However, frank \"tree-in-bud\" is less characteristic than in infection, and there is no exposure history provided.\n    *   Mycobacterium avium complex (MAC) infection (C): Patients with RA on MTX are immunosuppressed and at high risk for opportunistic infections, particularly NTM. The classic radiographic presentation of NTM is bronchiectasis with centrilobular nodules and tree-in-bud opacities. The biopsy finding of non-necrotizing granulomas is compatible with MAC (especially in the \"Lady Windermere\" or \"Hot Tub Lung\" phenotypes).\n\nThe combination of immunosuppression + tree-in-bud strongly favors infection. Among the choices, MAC fits the granulomatous pathology and imaging best.\n\nThe answer is (C)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-010", "question": "A 44-year-old woman presents with 8 months of progressive proximal muscle weakness, heliotrope rash, and Gottron's papules. Muscle biopsy shows perfascicular atrophy and MAC deposition on capillaries. She tests positive for anti-MDA5 antibodies. Which of the following complications carries the highest immediate mortality risk?", "options": ["Aspiration pneumonia", "Cardiac conduction abnormalities", "Rapidly progressive interstitial lung disease", "Malignancy-associated deterioration", "Calcinosis universalis"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 antibody-positive dermatomyositis is strongly associated with rapidly progressive interstitial lung disease (RP-ILD), which has mortality exceeding 50% within 6 months despite treatment. This subtype shows characteristic skin findings but often minimal muscle involvement, with MAC deposition on capillaries. While aspiration (A) and cardiac issues (B) occur in myositis, RP-ILD is the most lethal complication in anti-MDA5 patients. Malignancy risk (D) is lower with anti-MDA5 than with anti-TIF1γ. Calcinosis (E) is chronic but not immediately life-threatening. Early recognition and aggressive immunosuppression for RP-ILD are critical in anti-MDA5 dermatomyositis.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Here is the step-by-step reasoning for the answer:\n\n1.  Diagnosis: The patient presents with proximal muscle weakness, heliotrope rash, Gottron's papules, and specific biopsy findings (perifascicular atrophy, MAC deposition). These are classic features of Dermatomyositis (DM).\n\n2.  Specific Antibody Association: The patient tests positive for anti-MDA5 antibodies (Melanoma Differentiation-Associated gene 5).\n\n3.  Clinical Phenotype of Anti-MDA5: Anti-MDA5 positive dermatomyositis is a distinct phenotype. It is frequently associated with \"clinically amyopathic dermatomyositis\" (CADM) or DM with mild muscle involvement (though this patient has weakness, the antibody is the key prognostic factor here). Importantly, this antibody is strongly linked to unique cutaneous features (palmar papules, ulcerations) and a very specific, severe systemic complication.\n\n4.  Evaluating Complications:\n    *   Malignancy (Option D): Malignancy is a major concern in adult-onset DM, particularly associated with anti-TIF1- $\\gamma$ and anti-NXP2 antibodies. Anti-MDA5 is generally considered to have a lower risk of malignancy compared to these other subtypes.\n    *   Calcinosis (Option E): This is more commonly associated with juvenile DM and anti-NXP2 antibodies.\n    *   Rapidly Progressive Interstitial Lung Disease (Option C): Anti-MDA5 antibodies are notorious for their strong association with Rapidly Progressive Interstitial Lung Disease (RP-ILD). This form of ILD is aggressive, resistant to standard therapies, and carries a very high mortality rate (often citing survival rates <50-70% in certain cohorts due to respiratory failure) in the short term.\n    *   Aspiration Pneumonia (Option A): While pharyngeal weakness usually associated with severe muscle disease can lead to aspiration, the specific and disproportionately high immediate mortality risk associated with the *anti-MDA5* marker is driven by the lung parenchyma destruction (RP-ILD), not muscle weakness-induced aspiration.\n\n5.  Conclusion: The presence of anti-MDA5 antibodies flags the patient for the highest risk of Rapidly Progressive Interstitial Lung Disease, which determines the immediate prognosis and mortality risk.\n\nThe answer is (C)"}]